Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ralph Corey
Martin E Stryjewski

Showing results (31-40 of 194) with videos related to

Pageof 20
Sort By:
Expert Opinion on Pharmacotherapy|August 2, 2008
A new lipoglycopeptide: telavancinEsteban C Nannini, Martin E Stryjewski
Journal of Clinical Microbiology|October 23, 2009
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trialIn-Gyu Bae, Giang T Tonthat, Martin E Stryjewski, et al.
BMC Infectious Diseases|June 3, 2014
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE studyMartin E Stryjewski, Arnold Lentnek, William O'Riordan, et al.
International Journal of Antimicrobial Agents|July 30, 2013
Telavancin versus vancomycin for bacteraemic hospital-acquired pneumoniaMartin E Stryjewski, Steven L Barriere, Ethan Rubinstein, et al.
The American Journal of Medicine|March 5, 2005
Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremiaFadi El-Ahdab, Daniel Kelly Benjamin, Andrew Wang, et al.
International Journal of Antimicrobial Agents|September 9, 2008
Risk of intravascular cardiac device infections in patients with bacteraemia: impact on device removalG Ralph Corey, Tahaniyat Lalani
Infection and Drug Resistance|May 31, 2014
Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumoniaEthan Rubinstein, Martin E Stryjewski, Steven L Barriere
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 9, 2009
A balancing act: microbe versus muscleSara E Cosgrove, G Ralph Corey
Expert Opinion on Investigational Drugs|February 14, 2012
Tedizolid (TR-701): a new oxazolidinone with enhanced potencyZeina A Kanafani, G Ralph Corey
Future Microbiology|February 12, 2009
Ceftaroline: a cephalosporin with expanded Gram-positive activityZeina A Kanafani, G Ralph Corey
Pageof 20

Showing results (31-40 of 194) with videos related to

Sort By:
Pageof 20
Expert Opinion on Pharmacotherapy|August 2, 2008
A new lipoglycopeptide: telavancinEsteban C Nannini, Martin E Stryjewski
Journal of Clinical Microbiology|October 23, 2009
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trialIn-Gyu Bae, Giang T Tonthat, Martin E Stryjewski, et al.
BMC Infectious Diseases|June 3, 2014
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE studyMartin E Stryjewski, Arnold Lentnek, William O'Riordan, et al.
International Journal of Antimicrobial Agents|July 30, 2013
Telavancin versus vancomycin for bacteraemic hospital-acquired pneumoniaMartin E Stryjewski, Steven L Barriere, Ethan Rubinstein, et al.
The American Journal of Medicine|March 5, 2005
Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremiaFadi El-Ahdab, Daniel Kelly Benjamin, Andrew Wang, et al.
International Journal of Antimicrobial Agents|September 9, 2008
Risk of intravascular cardiac device infections in patients with bacteraemia: impact on device removalG Ralph Corey, Tahaniyat Lalani
Infection and Drug Resistance|May 31, 2014
Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumoniaEthan Rubinstein, Martin E Stryjewski, Steven L Barriere
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 9, 2009
A balancing act: microbe versus muscleSara E Cosgrove, G Ralph Corey
Expert Opinion on Investigational Drugs|February 14, 2012
Tedizolid (TR-701): a new oxazolidinone with enhanced potencyZeina A Kanafani, G Ralph Corey
Future Microbiology|February 12, 2009
Ceftaroline: a cephalosporin with expanded Gram-positive activityZeina A Kanafani, G Ralph Corey
Pageof 20